# OnCo record nct04538664 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04538664/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04538664", "NCT04538664" ;
  schema:name "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions"@en ;
  schema:alternateName "PAPILLON"@en ;
  schema:description "A phase 3 trial of Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04538664/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04538664> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-10-13" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04538664-n-engl-j-med-2023/> .